文献速递神经肌肉病

免疫球蛋白在重症肌无力中减少皮质类固醇用量的随机双盲安慰剂对照试验

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
PubMed 文献 · Neurology · 2022-10-21

这项随机双盲安慰剂对照试验纳入依赖皮质类固醇的AChR阳性重症肌无力患者,评估IGIV-C能否帮助减少皮质类固醇剂量。结果显示,IGIV-C组60.0%与安慰剂组63.3%的患者达到皮质类固醇剂量减少≥50%,组间无显著差异,次要终点亦无显著差异,IGIV-C耐受性良好。

要点

  • IGIV-C组60.0%与安慰剂组63.3%的患者达到皮质类固醇剂量减少≥50%,无显著差异。
  • 所有次要终点均无显著差异。
  • 安全性数据显示IGIV-C耐受性良好。

核心结论

  • 本研究中IGIV-C在减少每日皮质类固醇剂量方面并不优于安慰剂。
  • 这些结果提示IGIV-C与皮质类固醇的作用并非协同,机制可能不同。

研究设计与样本

  • 随机双盲安慰剂对照试验。
  • 纳入依赖皮质类固醇的重症肌无力患者(美国重症肌无力基金会分级II-Iva;AChR+)。

主要发现

  • 主要终点(皮质类固醇剂量减少≥50%)在IGIV-C组为60.0%,安慰剂组为63.3%,两组无显著差异。
  • 次要终点均无显著差异。
  • 安全性数据表明IGIV-C耐受性良好。

关键数值与推荐

  • 主要疗效终点(第39周)为皮质类固醇剂量减少≥50%。
  • IGIV-C负荷剂量为2 g/kg,分2天给予(每日最大80 g),第0周(基线)给药;维持剂量1 g/kg或安慰剂每3周一次至第36周;皮质类固醇减量自第9周开始并持续至第36周,除非患者恶化(定量MG评分较基线≥4分)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Myasthenia gravis (MG) is an autoimmune disease characterized by dysfunction at the neuromuscular junction. Treatment frequently includes corticosteroids (CSs) and IV immunoglobulin (IVIG). This study was conducted to determine whether immune globulin (human), 10% caprylate/chromatography purified (IGIV-C) could facilitate CS dose reduction in CS-dependent patients with MG. METHODS: In this randomized double-blind placebo-controlled trial, CS-dependent patients with MG (Myasthenia Gravis Foundation of America Class II-Iva; AChR+) received a loading dose of 2 g/kg IGIV-C over 2 days (maximum 80 g/d) or placebo at week 0 (baseline). Maintenance doses (1 g/kg IGIV-C or placebo) were administered every 3 weeks through week 36. Tapering of CS was initiated at week 9 and continued through week 36 unless the patient worsened (quantitative MG score ≥4 points from baseline). CS doses were increased (based on the current CS dose) in patients who worsened. Patients were withdrawn if worsening failed to improve within 6 weeks or if a second CS increase was required. The primary efficacy end point (at week 39) was a ≥50% reduction in CS dose. Secondary and safety end points were assessed throughout the study and follow-up (weeks 42 and 45). The study results and full protocol are available at clinicaltrials.gov/ct2/show/NCT02473965. RESULTS: The primary end point (≥50% reduction in CS dose) showed no significant difference between the IGIV-C treatment (60.0% of patients) and placebo (63.3%). There were no significant differences for secondary end points. Safety data indicated that IGIV-C was well tolerated. DISCUSSION: In this study, IGIV-C was not more effective than placebo in reducing daily CS dose. These results suggest that the effects of IGIV-C and CS are not synergistic and may be mechanistically different. TRIAL REGISTRATION INFORMATION: The trial was registered on clinicaltrialsregister.eu (EudraCT #: 2013-005099-17) and clinicaltrials.gov (identifier NCT02473965). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that IVIG infusions in adult patients with MG do not increase the percentage of patients achieving a ≥50% reduction in corticosteroid dose compared with placebo.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bril V, Szczudlik A, Vaitkus A, et al. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis. Neurology. 2022. PMID: 36270895. doi:10.1212/WNL.0000000000201501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。